Background: Latent tuberculosis infection (LTBI) is the primary source of active tuberculosis (ATB), but a preventive vaccine against LTBI is lacking.Methods: In this study, dominant helper T lymphocyte (HTL), cytotoxic T lymphocyte (CTL), and B-cell epitopes were identified from nine antigens related to LTBI and regions of difference (RDs).These epitopes were used to construct a novel multiepitope vaccine (MEV) based on their antigenicity, immunogenicity, sensitization, and toxicity.The immunol. characteristics of the MEV were analyzed with immunoinformatics technol. and verified by enzyme-linked immunospot assay and Th1/Th2/Th17 cytokine assay in vitro.Results: A novel MEV, designated PP19128R, containing 19 HTL epitopes, 12 CTL epitopes, 8 B-cell epitopes, toll-like receptor (TLR) agonists, and helper peptides, was successfully constructed.Bioinformatics anal. showed that the antigenicity, immunogenicity, and solubility of PP19128R were 0.8067, 9.29811, and 0.900675, resp.The global population coverage of PP19128R in HLA class I and II alleles reached 82.24% and 93.71%, resp.The binding energies of the PP19128R-TLR2 and PP19128R-TLR4 complexes were -1324.77 kcal/mol and -1278 kcal/mol, resp.In vitro experiments showed that the PP19128R vaccine significantly increased the number of interferon gamma-pos. (IFN-γ+) T lymphocytes and the levels of cytokines, such as IFN-γ, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-10.Furthermore, pos. correlations were observed between PP19128R-specific cytokines in ATB patients and individuals with LTBI.Conclusions: The PP19128R vaccine is a promising MEV with excellent antigenicity and immunogenicity and no toxicity or sensitization that can induce robust immune responses in silico and in vitro.This study provides a vaccine candidate for the prevention of LTBI in the future.
